Chris Storgard Net Worth

The estimated Net Worth of Chris Storgard is at least $146 Tysiąc dollars as of 23 November 2016. Chris Storgard owns over 37,593 units of Fate Therapeutics Inc stock worth over $145,861 and over the last 9 years Chris sold FATE stock worth over $0.

Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!

Sign up

Already have an account? Sign in

Chris Storgard FATE stock SEC Form 4 insiders trading

Chris has made over 1 trades of the Fate Therapeutics Inc stock since 2016, according to the Form 4 filled with the SEC. Most recently Chris bought 37,593 units of FATE stock worth $99,997 on 23 November 2016.

The largest trade Chris's ever made was buying 37,593 units of Fate Therapeutics Inc stock on 23 November 2016 worth over $99,997. On average, Chris trades about 9,398 units every 0 days since 2016. As of 23 November 2016 Chris still owns at least 37,593 units of Fate Therapeutics Inc stock.

You can see the complete history of Chris Storgard stock trades at the bottom of the page.

What's Chris Storgard's mailing address?

Chris's mailing address filed with the SEC is C/O FATE THERAPEUTICS, INC., 3535 GENERAL ATOMICS COURT, SUITE 200, SAN DIEGO, CA, 92121.

Insiders trading at Fate Therapeutics Inc

Over the last 11 years, insiders at Fate Therapeutics Inc have traded over $48,476,146 worth of Fate Therapeutics Inc stock and bought 11,483,795 units worth $162,421,037 . The most active insiders traders include Group, Llc Green Jeremy Red..., Associates V Lpvenrock Part... oraz Amir Nashat. On average, Fate Therapeutics Inc executives and independent directors trade stock every 26 days with the average trade being worth of $384,496. The most recent stock trade was executed by Yuan Xu on 6 August 2024, trading 633 units of FATE stock currently worth $2,678.

What does Fate Therapeutics Inc do?

fate therapeutics is applying leading expertise in stem cell biology and conventional drug discovery to develop small molecule and biologic drugs that: 1) activate stem cells in the body to stimulate healing and repair or block cancer growth; and 2) create and differentiate "pharmaceutical grade"​ ips cells to enable their use in drug discovery and development, disease modeling, and eventually personalized cell therapies. the company’s approach has broad therapeutic potential in areas such as regenerative medicine, hematological diseases, metastatic cancer, traumatic injury and degenerative diseases.

Complete history of Chris Storgard stock trades at Fate Therapeutics Inc

Fate Therapeutics Inc executives and stock owners

Fate Therapeutics Inc executives and other stock owners filed with the SEC include:

• John Wolchko,
  President, Chief Executive Officer, Director
• Bahram Valamehr,
  Chief Development Officer
• Cindy Tahl,
  General Counsel and Corporate Secretary
• Daniel Shoemaker,
  Chief Scientific Officer
• J. Scott Wolchko,
  Founder, CEO, Pres & Director
• Dr. Bahram Valamehr Ph.D.,
  Chief R&D Officer
• Cindy R. Tahl,
  Gen. Counsel & Corp. Sec.
• Karin Jooss,
  Independent Director
• Shefali Agarwal,
  Director
• William Rastetter,
  Independent Chairman of the Board
• Timothy Coughlin,
  Independent Director
• John Mendlein,
  Independent Vice Chairman of the Board
• Robert Epstein,
  Independent Director
• Michael Lee,
  Independent Director
• Edward Dulac,
  Chief Financial Officer
• Robert Hershberg,
  Director
• Renee Leck,
  IR Contact Officer
• Yu-Waye Chu,
  Vice President - Clinical Development
• Sarah Cooley,
  Senior Vice President - Clinical Translation
• Dr. Mark Plavsic D.V.M., Ph.D.,
  Chief Technical Officer
• Dr. Yu-Waye Chu M.D.,
  Sr. VP of Clinical Devel.
• Jim Beitel M.B.A.,
  Sr. VP of Corp. Devel.
• Dr. Wen Bo Wang,
  Sr. VP of Technical Operations
• Edward J. Dulac III,
  CFO & Principal Accounting Officer
• Mark J Enyedy,
  Director
• Stewart Abbot,
  Chief Development Officer
• Chris Storgard,
  Chief Medical Officer
• Amir Nashat,
  Director
• Brian T. Powl,
  Chief Commercial Officer
• J Scott Wolchko,
  President and CEO
• Group, Llc Green Jeremy Red...,
  
• Pratik S Multani,
  Chief Medical Officer
• Peter D Flynn,
  See remarks
• Christian Weyer,
  See remarks
• Venture Fund Vi Lparch Vent...,
  
• Venture Partners Vii Lpovp ...,
  
• Venture Management Co. V, L...,
  
• Robert Nelsen,
  Director
• Associates V Lpvenrock Part...,
  
• Yuan Xu,
  
• Mark Plavsic,
  Chief Technical Officer
• Neelufar Mozaffarian,